Document is current
Any future updates will be listed below
-
Authors
Nash, Pavel A
Turner, Keira M
Powell, Christopher A https://orcid.org/0000-0001-7501-0586
Van Haute, Lindsey https://orcid.org/0000-0001-7809-1473
Silva-Pinheiro, Pedro
Bubeck, Felix
Wiedtke, Ellen
Marques, Eloïse
Ryan, Dylan G
Grimm, Dirk https://orcid.org/0000-0001-6227-5665
Gammage, Payam A https://orcid.org/0000-0003-1968-1726
Minczuk, Michal https://orcid.org/0000-0001-8242-1420
-
Funding
Funding for this research was provided by:
UKRI | Medical Research Council (MC_UU_00015/4 and MC_UU_00028/3)
UKRI | Medical Research Council (MC_PC_21046)
The Lily Foundation
Champ Foundation
CRUK SI Core Funding (A31287)
A_BICR_1920_Gammage
- License Information
-
More Information
Article History
Received: 8 October 2024
Revised: 13 March 2025
Accepted: 14 March 2025
First Online: 9 April 2025
Disclosure and competing interests statement
: MM is a co-founder, shareholder, and member of the Scientific Advisory Board of Pretzel Therapeutics, Inc. PAG is a shareholder and provided consultancy services for Pretzel Therapeutics, Inc. PS-P and PAN provided consultancy services for Pretzel Therapeutics, Inc. LVH is director of NextGenSeek Ltd. The remaining authors declare no competing interests. PAG and MM are authors of a patent application WO2020188228A1 pertaining to the optimization and delivery of mitochondrial proteins in a single expression vector.
